Figures & data
Table 1. Comparative studies reporting PASI75/90/100 for ixekizumab in patients with psoriasis.
Table 2. Non-comparative studies reporting PASI75/90/100 for ixekizumab.
Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014; 14(8):a015354–a015354. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285. Lima XT, Minnillo R, Spencer JM, et al. Psoriasis prevalence among the 2009 AAD national melanoma/skin cancer screening program participants. J Eur Acad Dermatol Venereol. 2013;27(6):680–685. Parisi R, Symmons DP, Griffiths CE, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the Population-Based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665. Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):S216–S24. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265 e19. Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–451. Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220. Bulat V, Situm M, Delas Azdajic M, et al. Study on the impact of psoriasis on quality of life: psychological, social and financial implications. Psychiatr Danub. 2020;32(Suppl 4):553–561. Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):677–698. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. Gordon KB, Blauvelt A, Papp KA, UNCOVER-3 Study Group, et al. Phase 3 trials of ixekizumab in moderate-to-Severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681. Blauvelt A, Papp K, Gottlieb A, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358. Blauvelt A, Leonardi C, Elewski B, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058. Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70–79 e3. Reich K, Pinter A, Lacour JP, IXORA-S investigators, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.